| Literature DB >> 30124412 |
Yong Jun Choi, Yae-Jean Kim, Dongeun Yong, Jung-Hyun Byun, Taek Soo Kim, Yun Sil Chang, Min Ji Choi, Seung Ah Byeon, Eun Jeong Won, Soo Hyun Kim, Myung Geun Shin, Jong Hee Shin.
Abstract
We recently observed the emergence of fluconazole-resistant Candida parapsilosis bloodstream isolates harboring a Y132F substitution in Erg11p in South Korea. These Y132F isolates had a higher propensity to cause clonal transmission than other fluconazole-resistant isolates and persisted within hospitals for several years, as revealed by microsatellite typing.Entities:
Keywords: Candida parapsilosis; South Korea; antimicrobial resistance; candidemia; drug resistance; fluconazole; fungi; microsatellite marker
Mesh:
Substances:
Year: 2018 PMID: 30124412 PMCID: PMC6106402 DOI: 10.3201/eid2409.180625
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Molecular characterization of 47 fluconazole-resistant isolates and 20 fluconazole-susceptible isolates of Candida parapsilosis, South Korea*
| Microsatellite
genotypes† | Hospital | No. isolates | MICs, mg/L‡ |
| Amino acid substitutions§ | Isolation year (no. patients) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FLC | VRC | Erg11p | Mrr1p | Tac1p | Upc2p | |||||
| Fluconazole-resistant with Y132F in Erg11p, n = 30 isolates | ||||||||||
| M1 | A | 8 | 8–32 | 0.25–0.5 | Y132F | K177N | 2006 (1), 2009 (1), 2010 (2), 2011 (2), 2012 (1), 2013 (1) | |||
| B | 3 | 16–32 | 0.5 | Y132F | K177N | 2012 (2), 2013 (1) | ||||
| M2 | A | 10 | 8–32 | 0.125–0.5 | Y132F | K177N | 2012 (1), 2016 (9) | |||
| M3 | A | 3 | 8–16 | 0.25 | Y132F | K177N, Q1053* | 2007 (1), 2011 (1), 2012 (1) | |||
| M4 | A | 2 | 8–>64 | 0.5–4 | Y132F | K177N | 2013 (1), 2016 (1) | |||
| M5 | A | 1 | 32 | 0.25 | Y132F | K177N | 2012 (1) | |||
| M6 | A | 1 | 8 | 0.5 | Y132F | K177N | 2013 (1) | |||
| M7 | A | 1 | 8 | 0.25 | Y132F | K177N | 2016 (1) | |||
| M8 | C | 1 | 64 | 2 |
| Y132F |
|
|
| 2016 (1) |
| Other fluconazole-resistant, n = 17 isolates | ||||||||||
| M9 | D | 2 | >64 | 1 | G583R | 2007 (1), 2009 (1) | ||||
| M10 | E | 1 | 16 | 0.5 | R398I | L877P | 2005 (1) | |||
| M11 | A | 1 | 8 | 0.25 | 2006 (1) | |||||
| M12 | E | 1 | 8 | 0.25 | R398I | L877P | 2011 (1) | |||
| M13 | F | 1 | 16 | 0.06 | R398I | L877P | 2011 (1) | |||
| M14 | E | 1 | 8 | 0.125 | R398I | L877P | 2012 (1) | |||
| M15 | G | 1 | 8 | 0.125 | R398I | L877P | 2012 (1) | |||
| M16 | G | 1 | 8 | 0.06 | R398I | L877P | 2012 (1) | |||
| M17 | E | 1 | 8 | 0.125 | N900D | 2012 (1) | ||||
| M18 | C | 1 | 8 | 0.125 | R398I | P250S | L877P | 2012 (1) | ||
| M19 | C | 1 | 8 | 0.25 | R398I | S1081P | L877P | 2012 (1) | ||
| M20 | D | 1 | 8 | 0.125 | R398I | D394N | 2012 (1) | |||
| M21 | E | 1 | 32 | 0.5 | R398I | P295R | L877P | 2015 (1) | ||
| M22 | E | 1 | 16 | 0.125 | R398I | 2015 (1) | ||||
| M23 | H | 1 | 32 | 0.125 | K128N | W872C | 2015 (1) | |||
| M24 | E | 1 | 16 | 0.25 |
|
| G927D |
|
| 2016 (1) |
| Fluconazole-susceptible controls | ||||||||||
| M3 | A | 1 | 1 | 0.03 | K177N, Q1053* | 2010 (1) | ||||
| M25 | C | 2 | 0.5 | 0.03 | R398I | 2012 (2) | ||||
| M26 | F | 2 | 0.5 | 0.03–0.06 | R208G | 2012 (1), 2013 (1) | ||||
| M27 | A | 1 | 2 | 0.06 | 2010 (1) | |||||
| M28 | A | 1 | 0.5 | 0.03 | K177N, Q1053* | 2011 (1) | ||||
| M29 | A | 1 | 1 | 0.06 | L877P | 2011 (1) | ||||
| M30 | A | 1 | 1 | 0.03 | R208G | 2012 (1) | ||||
| M31 | A | 1 | 0.5 | 0.03 | R208G | 2012 (1) | ||||
| M32 | E | 1 | 2 | 0.03 | 2012 (1) | |||||
| M33 | G | 1 | 0.5 | 0.03 | R208G | 2012 (1) | ||||
| M34 | G | 1 | 0.5 | 0.03 | 2012 (1) | |||||
| M35 | A | 1 | 0.5 | 0.03 | R208G | 2013 (1) | ||||
| M36 | A | 1 | 1 | 0.06 | R398I | D394N | 2013 (1) | |||
| M37 | A | 1 | 0.5 | 0.03 | R398I | 2013 (1) | ||||
| M38 | D | 1 | 0.5 | 0.06 | R398I | 2014 (1) | ||||
| M39 | D | 1 | 0.5 | 0.06 | R208G | 2014 (1) | ||||
| M40 | E | 1 | 0.5 | 0.03 | R208G | 2015 (1) | ||||
| M41 | A | 1 | 1 | 0.03 | R398I | L877P | 2015 (1) | |||
*CLSI, Clinical and Laboratory Standards Institute; FLC, fluconazole; VRC, voriconazole. †For microsatellite typing, each strain was characterized by a genotype resulting from combination of the sizes of the 4 markers (CP1, CP4, CP6, and B). See the Technical Appendix Figure for results of microsatellite genotyping presented as an UPGMA tree. ‡Antifungal MICs were determined by the CLSI M27–A3 broth microdilution method (). The fluconazole MICs of 30 Y132F isolates determined by Etest were ≥8 mg/L. All 67 isolates tested were susceptible to amphotericin B (MIC 0.25–1 mg/L) and micafungin (MIC 0.25–2 mg/L) according to the CLSI method. §All were homozygote alleles except for 6 heterozygote alleles (Q1053,* G583R, P250S, P295R, W872C, and G927D) in Mrr1p.